16:05 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Ark's ziresovir stops worsening of RSV symptoms in Phase II

Ark Biosciences Inc. (Shanghai, China) reported data from the Phase II VICTOR trial in hospitalized infants with respiratory syncytial virus (RSV) infection showing that no infant who received a single dose of oral ziresovir (AK0529)...
20:48 , Nov 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Cell culture, mouse and rat studies identified an RSV F protein inhibitor that could help treat RSV infection. Optimization and testing in HeLa cell-based assays of a previously reported quinoline-based...
21:28 , Aug 1, 2018 |  BioCentury  |  Finance

Safety goes (Re)Viral

The clean safety profile and clinical efficacy of ReViral Ltd.’s respiratory syncytial virus therapy prompted Novo Ventures to co-lead the biotech’s $55 million series B round with fellow new investor New Leaf Venture Partners. The...
21:27 , Nov 10, 2017 |  BC Week In Review  |  Company News

Ark, Calibr in COPD deal

Ark Biosciences Inc. (Shanghai, China) partnered with the California Institute for Biomedical Research (La Jolla, Calif.) to develop “first-in-class” therapies for chronic obstructive pulmonary disease and related lung diseases. Ark said it will be responsible...
00:47 , Nov 8, 2017 |  BC Extra  |  Company News

Ark, Calibr in COPD deal

Ark Biosciences Inc. (Shanghai, China) partnered with the California Institute for Biomedical Research (La Jolla, Calif.) to develop “first-in-class” therapies for chronic obstructive pulmonary disease and related lung diseases. Ark said it will be responsible...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

AK0529: Phase II started

Ark began the double-blind, placebo-controlled, international Phase II VICTOR trial to evaluate single and multiple doses of oral AK0529 in about 80 hospitalized infants with RSV infection. Ark has exclusive, worldwide rights to develop and...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

AK0529: Phase I data

Top-line data from a double-blind, placebo-controlled, Australian Phase I trial in 64 healthy volunteers showed that single and multiple ascending doses of up to 1,200 mg oral AK0529 were well tolerated with no serious adverse...
00:31 , Apr 8, 2015 |  BC Extra  |  Financial News

Ark Biosciences raises series A round

Antiviral company Ark Biosciences Inc. (Shanghai, China) raised a series A round of undisclosed size. New investors Qiming Venture Partners and Morningside led the round, and existing investor TF Capital also participated. In October 2014,...